The combined safe dose was determined to be 3x106 units. The rate of complete tumour response was ~22% (95% CI), higher than nivolumab alone (~9%). Overall, IFNβ does not increase the rate of immune-related adverse events and may even enhance nivolumab’s anti-melanoma effects. The gene discussed is IFNB1; the disease is melanoma.